官方服务：
资源简介：
Medicaid Spending by Drug 2018-2022
2018-2022年度医疗保险药物支出数据集
应用场景：
创建时间：
2025-03-21
相关数据集
Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US
To provide the most current assessment of real-world healthcare resource utilization (HRU) and costs among patients with non-valvular atrial fibrillation (NVAF) who newly initiated rivaroxaban and api
DataCite Commons2022-08-03 更新90
Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China
Metastatic urothelial carcinoma (mUC) is challenging to treat, with 37% of patients failing first-line therapy. Effective second-line treatments, like Erdafitinib, are crucial. This study evaluates th
DataCite Commons2025-11-13 更新50
Results of scenario analyses for sCRT population.
Objective The effectiveness of sugemalimab vs. placebo in post-chemoradiotherapy patients with locally advanced, unresectable stage III NSCLC has been demonstrated and approved by China National Medic
NIAID Data Ecosystem20
Cost-consequence analysis of Pharmaceutical Care program for systemic arterial hypertension in the public health system in Brazil
ABSTRACT In Brazil, 80% of hypertensive patients have no blood pressure controlled, this fact has caused severe financial consequences for the public health system (PHS) and the Pharmaceutical Care (P
DataCite Commons2022-06-09 更新50
Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands
Background: Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA)
DataCite Commons2020-09-02 更新50
